Published in AIDS Weekly, March 6th, 1995
New assay systems using resting T cells - the major target for HIV in vivo - show that wild-type HIV is far more sensitive to neutralization by MAbs than previously was thought possible, reported New York University researcher Susan Zolla-Pazner during a plenary address to the Nineteenth AIDS Clinical Trial Group (ACTG) Meeting, held February 18-22, 1995, in Washington, D.C.
"We have to reexamine the issue of whether antibodies can neutralize primary isolates," she said.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.